IFNB1 and dermatomyositis: According to PubMed analysis (https://pubmed.ncbi.nlm.nih.gov/ (accessed on 4 August 2022), among the 43 drug candidates, 8 of the identified drugs are currently under pre-clinical testing for DM, including ruxolitinib [14], tofacitinib [15], upadacitinib [16], baricitinib [17], filgotinib [18], human interferon beta [19], interferon alfa-2a [20], and interferon beta-1 [21] (Table 3).